Beta-adrenergic blockers in mental retardation and developmental disabilities

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 5, Issue 4, 1999, Pages 290-298

  Ruedrich, Stephen ^a   Erhardt, Lendita ^a  

^a METROHEALTH MEDICAL CENTER   (United States)

Author keywords

Aggression; Anxiety; Beta adrenergic blockers; Neuroleptic induced akathisia; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ACEBUTOLOL; ADRENALIN; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BETAXOLOL; BISOPROLOL; CARTEOLOL; DOPAMINE; ESMOLOL; LABETALOL; METOPROLOL; NADOLOL; NEUROLEPTIC AGENT; NORADRENALIN; OXPRENOLOL; PENBUTOLOL; PINDOLOL; PROPRANOLOL; SOTALOL; TIMOLOL;

AGGRESSION; AKATHISIA; ANXIETY NEUROSIS; AUTOMUTILATION; BRONCHOSPASM; CONSTIPATION; DEVELOPMENTAL DISORDER; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG TOLERABILITY; HUMAN; INTELLECTUAL IMPAIRMENT; LIPOPHILICITY; MENTAL DEFICIENCY; NEUROCHEMISTRY; NEUROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SECOND MESSENGER;

EID: 0033378344     PISSN: 10804013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2779(1999)5:4<290::AID-MRDD6>3.0.CO;2-6     Document Type: Review

References (127)

1. Adler L, Angrist B, Peselow E, et al. 1985. Efficacy of propranolol in neuroleptic-induced akathisia. J Clin Psychopharmacol 5:164-166.
2. Adler L, Angrist B, Peselow E, et al. 1986. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 149:42-45.
3. Adler L, Angrist B, Weinreb H, et al. 1991. Studies on the time course and efficacy of beta blockers in neuroleptic-induced akathisia and the akathisia of idiopathic Parkinson's disease. Psychopharmacol Bull 27:107-111.
4. Adler LA, Peselow E, Rosenthal M, et al. 1993. A controlled comparison of the effects of propranolol, benztropine, and placebo on akathisia: an interim analysis. Psychopharmacol Bull 29:283-286.
5. Agras WS. 1990. Treatment of social phobias. J Clin Psychiatry 51(suppl):52-55.
6. Allan ER, Alpert M, Sison LE, et al. 1996. Adjunctive nadolol in the treatment of acutely aggressive schizophrenic patients. J Clin Psychiatry 57:455-459.
7. Alpert M, Allas ER, Citrome L, et al. 1990. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol Bull 26:367-371.
8. Aanth J. 1986. Propranolol in psychiatry: therapeutic uses and side effects. Neuropsychobiology 10:20-27.
9. Arnold LE, Aman MG. 1991. Beta blockers in mental retardation and developmental disorders. J Child Adolesc Psychopharmacol 1:361-373.
10. Artigas F. 1995. Pindolol, 5 hydroxytryptamine and antidepressant augmentation. Arch Gen Psychiatry 52:969-971.
11. Avorn J, Everitt DE, Weiss S. 1986. Increased antidepressant use in patients prescribed beta blockers. J Am Med Assoc 255:357-360.
12. Ballenger JC, Davidson JRT, Lecrubier Y, et al. 1998. Consensus statement on social anxiety disorder for the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 59 (suppl):54-60.
13. Baumeister AA, Sevin JA. 1990. Pharmacologic control of aberrant behavior in the mentally retarded: toward a more rational approach. Neurosci Biobehav Rev 14:253-262.
14. Berlant JL. 1987. One more look at propranolol for the treatment of refractory schizophrenia. Schizophr Bull 13:705-714.
15. Berman RM, Darnell AM, Miller HL, et al. 1997. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am J Psychiatry 154:37-43.
16. Blaisdell GD. 1994. Akathisia: a comprehensive review and treatment summary. Pharmacopsychiatry 27:139-146.
17. Bodfish JW, Newell KM, Sprague RL, et al. 1997. Akathisia in adults with mental retardation: development of the Akathisia Ratings of Movement Scale (ARMS). Am J Ment Retard 101:413-423.
18. Botschev C, Bondy B, Hofmann M, et al. 1996. B2-receptor density on mononuclear blood cells in patients suffering from neuroleptic-induced akathisia (NIA). Biol Psychiatry 40:203-207.
19. Brantigan CO, Brantigan TA, Joseph N. 1982. Effect of beta-blockade and beta-stimulation on stage fright. Am J Med 72:88-94.
20. Braude WM, Barnes TR, Gore S. 1983. Clinical investigation of akathisia: a systematic investigation of acute psychiatric inpatient admissions. Br J Psychiatry 143:139-150.
21. Bright RA, Everitt DE. 1992. B-blocker and depression: evidence against an association. J Am Med Assoc 267:1783-1787.
22. Buitelaar JK, van der Gaag RJ, Swaab-Barneveld H, et al. 1994. A placebo-controlled comparison of methylphenidate and pindolol in ADHD. Scientific Proceedings of the American Society of Child and Adolescent Psychiatry, 10:43.
23. Calamari JE, McNally RJ, Benson DS, et al. 1990. Case study: use of propranolol to reduce aggressive behavior in a woman who is mentally retarded. Behav Resident Treat 5:287-296.
24. Carlsson C, Johansson T. 1971. The psychological effects of propranolol in the abstinence phase of chronic alcoholics. Br J Psychiatry 119:605-606.
25. Coccaro EF. 1989. Central serotonin and impulsive aggression. Br J Psychiatry 155(suppl 8): 52-62.
26. Cohen IL, Tsioris JA, Pfadt A. 1991. Effects of long-acting propranolol on agonistic and stereotyped behaviors in a man with pervasive developmental disorder and fragile X syndrome: a double-blind, placebo-controlled study. J Clin Psychopharmacol 11:398-399.
27. Collins S, Caron MG, Lefkowitz RJ. 1991. Regulation of adrenergic receptor responsiveness through modulation of receptor gene expression. Annu Rev Physiol 53:497-508.
28. Connor DF. 1993. Beta blockers for aggression: a review of the pediatric experience. J Child Adolesc Psychopharmacol 3:99-114.
29. Connor DF. 1994. Nadolol for self-injury, overactivity, inatttention, and aggression in a child with pervasive developmental disorder. J Child Adolesc Psychopharmacol 4:101-111.
30. Connor DF, Ozbayrale KR, Benjamin S, et al. 1997. A pilot study of nadolol for overt aggression in developmentally delayed individuals. J Acad Child Adolesc Psychiatry 36:826-834.
31. Conway J, Greenwood DT, Middlemiss C. 1978. Central nervous actions of beta adrenoreceptor antagonists. Clin Sci Mol Med 54:119-124.
32. Covelli V, Antonacci F, Pagliarulo E. 1983. Propranolol: further evidence of its antianxiety effect. Acta Pharm 9:367-373.
33. Cruickshank JM, Pritchard BNC. 1987. Beta blockers in clinical practice. Edinburgh: Churchill Livingstone.
34. Currie D, Lewis RV, McDevitt DG, et al. 1988. Central effects of beta-adrenergic antagonists, 1. Performance and subjective assessment of mood. Br J Clin Pharmacol 26:121-128.
35. Diamond S, Kudrow L, Stevens J, et al. 1982. Long-term study of propranolol in the treatment of migraine. Headache 22:268-271.
36. Drew PJT, Barnes JN, Evans SJ. 1985. The effect of acute beta-adrenergic blockade on examination performance. Br J Clin Pharmacol 19:783-786.
37. Duman JP, Caatteau J, Lanvin F, et al. 1992. Randomized, double-blind crossover placebo-controlled comparison of propranolol and betaxolol in the treatment of neuroleptic-induced akathisia. Am J Psychiatry 145:647-650.
38. Dumon RS, Nestler EJ. 1995. Signal transduction pathways for catecholamine receptors. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology, the fourth generation of progress. New York: Raven Press. p 303-320.
39. Dural CA, Krantz DS, Barrett JE. 1986. The antianxiety effect of beta-blockers on punished responding. Pharmacol Biochem Behav 25:371-374.
40. Eichelman B. 1987. Neurochemical bases of aggressive behavior. Psychiatric Ann 17:371-384.
41. Eimer M. 1989. Management of the behavioral symptoms associated with dementia. Prime Care 16:431-450.
42. Elliott FA. 1977. Propranolol for the control of belligerent behavior following acute brain damage. Ann Neurol 1:489-491.
43. Fahs JJ. 1989. Anxiety disorders. In: Karasu TB, editor. Treatments of psychiatric disorders: a task force report of the American Psychiatric Association. Washington, DC: American Psychiatric Association. p 14-19, 85-90.
44. Findley LJ, Koller WC. 1987. Essential tremor: a review. Neurology 37:1194-1197.
45. Fleischhacker WW, Bergman KJ, Perovich R. 1989. The Hillside Akathisia Scale: a new rating instrument for neuroleptic-induced akathisia. Psychopharmacol Bull 25:222-226.
46. Fraser WI, Ruedrich SL, Kerr M, et al. 1998. Beta-adrenergic blockers. In: Reiss S, Aman MG, editors. Psychotropic medication and developmental disabilities. The international consensus handbook. Columbus, OH: Nisonger Center/Ohio State University. p 271-290.
47. Gaby NS, Lefkowitz DS, Israel JR. 1983. Treatment of lithium tremor with metoprolol. Am J Psychiatry 140:593-595.
48. Ganesh S, Rao M, Cowie VA. 1989. Akathisia in neuroleptic medicated mentally handicapped subjects. J Ment Defic Res 33:323-329.
49. Gerstman BB, Jolson HM, Bauer M, et al. 1996. The incidence of depression in new users of beta-blockers and selected antihypertensives. J Clin Epidemiol 49:809-815.
50. Gillette DW, Tannery LP. 1994. Beta blocker inhibits tricyclic metabolism. J Am Acad Child Adolesc Psychiatry 33:223-224.
51. Gleiter CH, Deckert J. 1996. Adverse CNS-effects of beta-adrenoreceptor blockers. Pharmacopsychiatry 29:201-211.
52. Glemmon RA, Dukat AM. 1995. Serotonin receptor subtypes. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology, the fourth generation of progress. New York: Raven Press. p 415-429.
53. Goldstein M. 1974. Brain research and violent behavior. Arch Neurol 30:1-35.
54. Gorman JM, Levy GF, Liebowitz MR, et al. 1983. Effect of acute beta-adrenergic blockade on lactate-induced panic. Arch Gen Psychiatry 40:1079-1082.
55. Granville-Grossman KL, Turner P. 1966. The effect of propranolol on anxiety. Lancet 1:788-790.
56. Greendyke RM, Kanter DR. 1986. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry 47:423-426.
57. Greendyke RM, Kanter DR, Schuster DB, et al. 1986. Propranolol treatment of assaultive patients with organic brain disease. J Nerv Ment Dis 174:290-294.
58. Greendyke RM, Berkner JP, Webster JC, et al. 1989. Treatment of behavioral problems with pindolol. Psychosomatics 30:161-165.
59. Gross EJ, Hull HG, Lytton GT, et al. 1993. Case study of neuroleptic-induced akathisia: important implications for individuals with mental retardation. Am J Ment Retard 98:156-164.
60. Gualtieri CT. 1993. The problem of tardive akathisia. Brain Cogn 23:102-109.
61. Haspel T. 1995. Beta blockers and the treatment of aggression. Harvard Rev Psychiatry 2:274-281.
62. Hayes PE, Schulz SC. 1987. The use of beta-adrenergic blocking agents in anxiety disorders and schizophrenia. Pharmacotherapy 3:101-117.
63. Higley JD, Mehlman PT, Taub DM, et al. 1992. Cerebrospinal fluid monoamine and adrenal correlates of aggression in free-ranging rhesus monkeys. Arch Gen Psychiatry 49:436-441.
64. Hoffman BB, Lefkowitz RJ. 1996. Catecholemines, sympathominetic drugs, and adrenergic receptor antagonists. In: Hardman JG, Gilman AG, Limbird LE, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 9th edition. New York: McGraw-Hill. p 199-248.
65. Holloman C, Marder SR. 1997. Management of acute extrapyramidal effects induced by antipsychotic drugs. Am J Health Syst Pharmacy 54:2461-2477.
66. James IM, Griffith DNW, Pearson RM, et al. 1977. Effect of oxprenolol on stage fright in musicians. Lancet 2:952-954.
67. Jenkins SC, Maruta T. 1987. Therapeutic use of propranolol for intermittent explosive disorder. Mayo Clin Proc 62:204-214.
68. Kaplan H, Sadock B. 1998. Synopsis Psychiatry 8:102-104.
69. Kastner T, Burlingham K, Friedman DL. 1990. Metoprolol for aggressive behavior in persons with mental retardation. Am Fam Physician 42:1559-1588.
70. Kathol RG, Noyes R, Slyman DJ, et al. 1980. Propranolol in chronic anxiety disorders. Arch Gen Psychiatry 37:1361-1365.
71. King NJ, Ollendick TH, Gullone E, et al. 1990. Fear and phobias in children and adolescents with intellectual disabilities: assessment and intervention strategies. Aust NZ J Dev Disabil 16:97-108.
72. Kobilka B. 1991. Adrenergic receptors as models for G protein coupled receptors. Annu Rev Neurosci 15:87-114.
73. Kraus ML, Gottlieb LD, Horwitz RI, et al. 1985. Randomized clinical trial of atenolol in patients with alcohol withdrawal. N Engl J Med 313:905-909.
74. Kuperman S, Stewart MA. 1987. Use of propranolol to decrease aggressive outbursts in younger patients. Psychosomatics 28:315-319.
75. Lader M. 1988. Beta adrenoceptor antagonists in neuropsychiatry: an update. J Clin Psychiatry 49:213-223.
76. Lang C, Remington D. 1994. Treatment with propranolol of severe self-injurious behavior in a blind, deaf, retarded adolescent. J Am Acad Child Adolesc Psychiatry 33:265-269.
77. Lavine R. 1997. Psychopharmacological treatment of aggression and violence in the substance using population. J Psychoactive Drugs 29: 321-329.
78. Levine HG. 1985. Situational anxiety and everyday life experiences of mildly mentally retarded adults. Am J Ment Defic 90:27-33.
79. Lewis RV, Lofthouse C. 1993. Adverse reactions with beta-adrenergic blocking drugs. Drug Safety 9:272-279.
80. Liebowitz MR, Schneier F, Campcos R, et al. 1992. Phenelzine vs aterodol in social phobic: a placebo-controlled comparison. Arch Gen Psychiatry 49:290-300.
81. Lipinski JF, Zubenko GS, Cohen BM, et al. 1984. Propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 141:412-415.
82. Luchins DJ, Dojka MS. 1989. Lithium and propranolol in aggression and self-injurious behavior in the mentally retarded. Psychopharmacol Bull 25:372-375.
83. Mattes JA. 1985. Metoprolol for intermittent explosive disorder. Am J Psychiatry 142:1108-1109.
84. Mattes JA. 1990. Comparative effectiveness of carbamazepine and propranolol for rage outbursts. J Neuropsychiatry 2:159-164.
85. Matthews-Ferrari K, Karroum N. 1992. Metoprolol for aggression [Letter to the editor.] J Am Acad Child Adolesc Psychiatry 31:994.
86. Matuzas W, Jack E. 1991. The drug treatment of panic disorders. Psychol Med 9:213-215.
87. McAnish J, Cruickshank JM. 1990. Beta Mockers and central nervous system side effects. Pharmacol Ther 46:163-197.
88. McElroy JP, Weider PJ, Smith TE, et al. 1996. Treatment of schizophrenia: the expert consensus guideline series. J Clin Psychiatry 57(suppl 12B).
89. Meibach RC, Mullane JF, Binstok G. 1987. A placebo-controlled multi-center trial of propranolol and chlordiazepoxide in the treatment of anxiety. Crit Ther Res 41:65-76.
90. Noyes R Jr. 1985. Beta-adrenergic blocking drugs in anxiety and stress. Psychiatr Clin North Am 8:119-132.
91. Pabis DJ, Stanislav SW. 1996. Pharmacotherapy of aggressive behavior. Ann Pharmacother 30: 278-287.
92. Palacios JR, Kuhar MJ. 1980. Beta adrenergic receptor localization by light microscopic autoradiography. Science 208:1378-1380.
93. Peet M, Ali S. 1986. Propranolol and atenolol in the treatment of anxiety. Int J Psychopharmacol 1:314-319.
94. Penney JB Jr. 1996. Neurochemical neuroanatomy. In: Fogel BS, Schiffer RB, Rao SM, editors. Neuropsychiatry. Baltimore: Williams and Wilkins. p 159-160.
95. Perez V, Gilaberte I, Faries D, et al. 1997. Randomized, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349:1594-1597.
96. Peroutka SJ. 1990. The pharmacology of current anti-migraine drugs. Headache 30(suppl 1): 5-11.
97. Polakoff SA, Sorgi PJ, Ratey JJ. 1986. The treatment of impulsive and aggressive behavior with nadolol. J Clin Psychopharmacol 6:125-126.
98. Pollack MH. 1999. Social anxiety disorder: designing a pharmacologic treatment strategy. J Clin Psychiatry 60(suppl 9):20-26.
99. Rapoport A, Stein D, Grinshpoon A, et al. 1994. Akathisia and pseudoakathisia: clinical observations and accelerometer recordings. J Clin Psychiatry 55:473-477.
100. Ratey JJ, Lindem KJ. 1991. Beta blockers as primary treatment for aggression and self-injury in the developmentally disabled. In: Ratey JJ, editor. Mental retardation: developing pharmacotherapies. Washington, DC: American Psychiatric Association. p 51-82.
101. Ratey JJ, Morrill R, Oxenkrug O. 1983. Use of propranolol for provoked and unprovoked episodes of rage. Am J Psychiatry 140:1356-1357.
102. Ratey JJ, Mikkelsen EJ, Smith GB, et al. 1986. Beta blockers in the severely and profoundly mentally retarded. J Clin Psychopharmacol 6:103-107.
103. Ratey JJ, Mikkelsen E, Sorgi P, et al. 1987. Autism: the treatment of aggressive behaviors. J Clin Psychopharmacol 7:35-41.
104. Ratey JJ, Greenberg MS, Lindem KJ. 1991. Combination of treatment for attention deficit hyperactivity disorder in adults. J Nerv Ment Dis 179:699-701.
105. Ratey JJ, Sorgi P, O'Driscoll GA, et al. 1992. Nadolol to treat aggression and psychotic symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J Clin Psychiatry 53:41-46.
106. Reiss S. 1994. Handbook of challenging behavior: mental health aspect: of mental retardation. Worthington, OH: IDS Publishing.
107. Ruedrich SL. 1996. Beta adrenergic blocking medications for treatment of rage outbursts in mentally retarded persons. Semin Clin Neuropsychiatry 1:115-121.
108. Ruedrich SL, Grush L, Wilson J. 1990. Beta adrenergic blocking medications for aggressive or self-injurious mentally retarded persons. Am J Ment Retard 95:110-119.
109. Sachdev P. 1994. A rating scale for acute drug-induced akathisia: development, reliability and validity. Biol Psychiatry 35:263-271.
110. Salmon P, Gray JA. 1986. Effects of propranolae on conditioned suppression, discriminated punishment and discriminated nonreward in the rat. Psychopharmacol 88:252-257.
111. Sands S, Ratey JJ. 1986. The concept of noise. Psychiatry 49:290-297.
112. Saul P, Jones BP, Edwards KG, Tweed JA. 1985. Randomized comparison of atenolol and placebo in the treatment of anxiety: a double-blind study. Eur J Clin Pharmacol 28(suppl):109-110.
113. Schlager D. 1994. Early morning administration of short-acting beta blockers for treatment of winter depression. Am J Psychiatry 151:1383-1385.
114. Schwartz JH, Kandel ER. 1991. Synaptic transmission mediated by second messengers. In: Kandel ER, Schwartz JH, Jessell TM, editors. Principles of Neuronal Science. 3rd edition. Elsevier, New York. p 174-193.
115. Sims J, Galvin MR. 1990. Pediatric psychopharmacologic uses of propranolol. J Child Adolesc Psychiatry Ment Health Nurs 3:18-24.
116. Solomon S, Hutchkiss E, Saravoy SM, et al. 1983. Impairment of memory function by antihypertensive medication. Arch Gen Psychiatry 41:1109-1112.
117. Sorgi P, Ratey JJ, Knoedler D, et al. 1992. Depression during treatment with beta blockers: results from a double-blind, placebo-controlled study. J Neuropsychiatry Clin Neurosci 4:187-189.
118. Stone RK, May JE, Alvarez WF, et al. 1989. Prevalence of dyskinesia and related movement disorders in a developmentally disabled population. J Ment Defic Res 33:41-53.
119. Tyrer P. 1988. Current status of beta-blocking drugs in the treatment of anxiety disorders. Drugs 36:773-783.
120. Van Kammen DP, Peters J, Yao J. et al. 1990. Norepinephrine in acute exacerbations of chronic schizophrenia. Arch Gen Psychiatry 47:161-168.
121. Widerhorn J, Rubin JN, Frishman WH, et al. 1987. Cardiovascular drugs in pregnancy. Cardiol Clin 5:651-674.
122. Williams DT, Mehl R, Yudofsky S, et al. 1982. The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. J Am Acad Child Psychiatry 21:129-135.
123. Wolfensberger W, Menolascino F. 1970. Methodological considerations in evaluating the intelligence-enhancing properties of drugs. In: Menolascino F, editor. Psychiatric approaches to mental retardation. New York: Basic Books. p 399-421.
124. Yudofsky SC. 1992. Beta blockers and depression: the clinician's dilemma. J Am Med Assoc 267:1826-1827.
125. Yudofsky SC, Williams D, Gorman J. 1981. Propranolol in the treatment of rage and violent behavior in patients with chronic brain syndrome. Am J Psychiatry 138:218-230.
126. Zanardi R, Argas F, Franchini L, et al. 1997. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol 17:446-450.
127. Zubenko GS, Lipinski JF, Colon BM, et al. 1985. Comparison of metoprolol and propranolol in the treatment of akathisia. Psychiatr Res 11:143-149.